Business UpdateSep 10, 2026, 04:08 PM
Yarrow Bioscience Presents YB-101 for Graves' Disease & Thyroid Eye Disease
AI Summary
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) has released an investor presentation detailing its lead product candidate, YB-101, an anti-TSHR antibody targeting Graves' Disease (GD) and Thyroid Eye Disease (TED). The company is advancing YB-101 into Phase 2 trials for GD, with a Fast Track designation from the FDA and an anticipated Phase 2a readout in the second half of 2027. Yarrow has raised $200 million to date, providing runway into 2028, and has in-licensed rights to YB-101 outside of China from GenSci, which is conducting ongoing Phase 1 studies.
Key Highlights
- Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) released an investor presentation on September 10, 2026.
- The presentation details YB-101, a potential first-in-class anti-TSHR antibody for Graves' Disease and Thyroid Eye Disease.
- YB-101 is in Phase 2 development for Graves' Disease, with Phase 2a readout anticipated in 2H 2027.
- The company raised $200M to date, with cash runway expected into 2028.
- Yarrow in-licensed exclusive rights to YB-101 for GD and TED outside greater China in December 2025.
- GenSci is conducting Phase 1 studies with YB-101 in China for both GD and TED.
Price Impact
More from VYNE